Moonlighting proteins in cancer

Cancer Letters

Volumn 370, Issue 1, 2016, Pages 108-116

  Min, Kyung Won ^a,c   Lee, Seong Ho ^b   Baek, Seung Joon ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Dynamic proteins; Moonlighting protein; Multi functional proteins; Translocation

Indexed keywords

BETA CATENIN; CWP 232228; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GROWTH DIFFERENTIATION FACTOR 15; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HIGH MOBILITY GROUP B1 PROTEIN; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MOONLIGHTING PROTEIN; PEPTIDES AND PROTEINS; PROTEIN ESE 1; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN INHIBITOR; PROTEIN MDM2 INHIBITOR; PROTEIN P53; PROTEIN P53 INHIBITOR; SMAD PROTEIN; SMAD2 PROTEIN; SMAD4 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; STROMELYSIN; TOLFENAMIC ACID; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

COLON CANCER; DRUG PROTEIN BINDING; HEMATOLOGIC MALIGNANCY; HUMAN; INTRACELLULAR SIGNALING; NEOPLASM; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SHORT SURVEY; SOLID TUMOR; STOMACH CANCER; METABOLISM; PHYSIOLOGY;

GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; GTP-BINDING PROTEINS; HMGB1 PROTEIN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS; PROTEINS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SMAD PROTEINS; TRANSGLUTAMINASES;

EID: 84949477592     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.09.022     Document Type: Review

References (129)

1. Parras-Molto M., Campos-Laborie F., Garcia-Dieguez J., Rodriguez-Grinolo M., Perez-Pulido A. Classification of protein motifs based on subcellular localization uncovers evolutionary relationships at both sequence and functional levels. BMC Bioinformatics 2013, 14:229.
2. Jeffery C.J. Moonlighting proteins. Trends Biochem. Sci 1999, 24:8-11.
3. Jeffery C.J. Moonlighting proteins: old proteins learning new tricks. Trends Genet 2003, 19:415-417.
4. Huberts D.H.E.W., van der Klei I.J. Moonlighting proteins: an intriguing mode of multitasking. Biochim. Biophys. Acta 2010, 1803:520-525.
5. Jeffery C.J. Moonlighting proteins-an update. Mol. Biosyst 2009, 5:345-350.
6. Isaacs J.S., Xu W., Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3:213-217.
7. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5:761-772.
8. Wang X., Song X., Zhuo W., Fu Y., Shi H., Liang Y., et al. The regulatory mechanism of Hsp90α secretion and its function in tumor malignancy. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:21288-21293.
9. Eustace B.K., Sakurai T., Stewart J.K., Yimlamai D., Unger C., Zehetmeier C., et al. Functional proteomic screens reveal an essential extracellular role for hsp90[alpha] in cancer cell invasiveness. Nat. Cell Biol 2004, 6:507-514.
10. Song X., Wang X., Zhuo W., Shi H., Feng D., Sun Y., et al. The regulatory mechanism of extracellular Hsp90α on matrix metalloproteinase-2 processing and tumor angiogenesis. J. Biol. Chem 2010, 285:40039-40049.
11. Hance M.W., Dole K., Gopal U., Bohonowych J.E., Jezierska-Drutel A., Neumann C.A., et al. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J. Biol. Chem 2012, 287:37732-37744.
12. Csermely P., Schnaider T., Soti C., Prohászka Z., Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther 1998, 79:129-168.
13. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 2010, 10:537-549.
14. Jhaveri K., Taldone T., Modi S., Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim. Biophys. Acta 1823, 2012:742-755.
15. Wang Y., Trepel J.B., Neckers L.M., Giaccone G. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr. Opin. Investig. Drugs 2010, 11:1466-1476.
16. Lorand L., Graham R.M. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol 2003, 4:140-156.
17. Park D., Choi S., Ha K.-S. Transglutaminase 2: a multi-functional protein in multiple subcellular compartments. Amino Acids 2010, 39:619-631.
18. Cao L., Petrusca D.N., Satpathy M., Nakshatri H., Petrache I., Matei D. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis 2008, 29:1893-1900.
19. Iismaa S.E., Wu M.-J., Nanda N., Church W.B., Graham R.M. GTP binding and signaling by Gh/transglutaminase II involves distinct residues in a unique GTP-binding pocket. J. Biol. Chem 2000, 275:18259-18265.
20. Mishra S., Murphy L.J. Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J. Biol. Chem 2004, 279:23863-23868.
21. Lesort M., Attanavanich K., Zhang J., Johnson G.V.W. Distinct nuclear localization and activity of tissue transglutaminase. J. Biol. Chem 1998, 273:11991-11994.
22. Mann A.P., Verma A., Sethi G., Manavathi B., Wang H., Fok J.Y., et al. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-κB in cancer cells: delineation of a novel pathway. Cancer Res 2006, 66:8788-8795.
23. Peng X., Zhang Y., Zhang H., Graner S., Williams J.F., Levitt M.L., et al. Interaction of tissue transglutaminase with nuclear transport protein importin-α3. FEBS Lett 1999, 446:35-39.
24. Oliverio S., Amendola A., Di Sano F., Farrace M.G., Fesus L., Nemes Z., et al. Tissue transglutaminase-dependent posttranslational modification of the retinoblastoma gene product in promonocytic cells undergoing apoptosis. Mol. Cell. Biol 1997, 17:6040-6048.
25. Filiano A.J., Bailey C.D.C., Tucholski J., Gundemir S., Johnson G.V.W. Transglutaminase 2 protects against ischemic insult, interacts with HIF1β, and attenuates HIF1 signaling. FASEB J. 2008, 22:2662-2675.
26. Tatsukawa H., Fukaya Y., Frampton G., Martinez-Fuentes A., Suzuki K., Kuo T.F., et al. Role of transglutaminase 2 in liver injury via cross-linking and silencing of transcription factor Sp1. Gastroenterology 2009, 136:1783-1795. e1710.
27. Mishra S., Saleh A., Espino P.S., Davie J.R., Murphy L.J. Phosphorylation of histones by tissue transglutaminase. J. Biol. Chem 2006, 281:5532-5538.
28. Collighan R.J., Griffin M. Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications. Amino Acids 2009, 36:659-670.
29. Akimov S.S., Belkin A.M. Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood 2001, 98:1567-1576.
30. Telci D., Wang Z., Li X., Verderio E.A.M., Humphries M.J., Baccarini M., et al. Fibronectin-tissue transglutaminase matrix rescues RGD-impaired cell adhesion through syndecan-4 and β1 integrin Co-signaling. J. Biol. Chem 2008, 283:20937-20947.
31. Yakubov B., Chen L., Belkin A.M., Zhang S., Chelladurai B., Zhang Z.Y., et al. Small molecule inhibitors target the tissue transglutaminase and fibronectin interaction. PLoS ONE 2014, 9:e89285.
32. Sirover M.A. Subcellular dynamics of multifunctional protein regulation: mechanisms of GAPDH intracellular translocation. J. Cell. Biochem 2012, 113:2193-2200.
33. Tristan C., Shahani N., Sedlak T.W., Sawa A. The diverse functions of GAPDH: views from different subcellular compartments. Cell. Signal 2011, 23:317-323.
34. Hara M.R., Agrawal N., Kim S.F., Cascio M.B., Fujimuro M., Ozeki Y., et al. S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat. Cell Biol 2005, 7:665-674.
35. Sen N., Hara M.R., Kornberg M.D., Cascio M.B., Bae B.-I., Shahani N., et al. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat. Cell Biol 2008, 10:866-873.
36. Azam S., Jouvet N., Jilani A., Vongsamphanh R., Yang X., Yang S., et al. Human glyceraldehyde-3-phosphate dehydrogenase plays a direct role in reactivating oxidized forms of the DNA repair enzyme APE1. J. Biol. Chem 2008, 283:30632-30641.
37. Dai R.-P., Yu F.-X., Goh S.-R., Chng H.-W., Tan Y.-L., Fu J.-L., et al. Histone 2B (H2B) expression is confined to a proper NAD+/NADH redox status. J. Biol. Chem 2008, 283:26894-26901.
38. Demarse N.A., Ponnusamy S., Spicer E.K., Apohan E., Baatz J.E., Ogretmen B., et al. Direct binding of glyceraldehyde 3-phosphate dehydrogenase to telomeric DNA protects telomeres against chemotherapy-induced rapid degradation. J. Mol. Biol 2009, 394:789-803.
39. Chou D.K.H., Evans J.E., Jungalwala F.B. Identity of nuclear high-mobility-group protein, HMG-1, and sulfoglucuronyl carbohydrate-binding protein, SBP-1, in brain. J. Neurochem 2001, 77:120-131.
40. Bianchi M.E., Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Curr. Opin. Genet. Dev 2005, 15:496-506.
41. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol 2005, 5:331-342.
42. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
43. Diener K.R., Al-Dasooqi N., Lousberg E.L., Hayball J.D. The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and cancer. Immunol. Cell Biol 2013, 91:443-450.
44. Sims G.P., Rowe D.C., Rietdijk S.T., Herbst R., Coyle A.J. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol 2010, 28:367-388.
45. Abe A., Kuwata T., Yamauchi C., Higuchi Y., Ochiai A. High Mobility Group Box 1 (HMGB1) released from cancer cells induces the expression of pro-inflammatory cytokines in peritoneal fibroblasts. Pathol. Int 2014, 64:267-275.
46. Kruse J.-P., Gu W. Modes of p53 regulation. Cell 2009, 137:609-622.
47. Riley T., Sontag E., Chen P., Levine A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol 2008, 9:402-412.
48. Chipuk J.E., Bouchier-Hayes L., Kuwana T., Newmeyer D.D., Green D.R. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005, 309:1732-1735.
49. You H., Yamamoto K., Mak T.W. Regulation of transactivation-independent proapoptotic activity of p53 by FOXO3a. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:9051-9056.
50. Marchenko N.D., Wolff S., Erster S., Becker K., Moll U.M. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J. 2007, 26:923-934.
51. Chipuk J.E. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303:1010-1014.
52. Green D.R., Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009, 458:1127-1130.
53. Foo R.S. Regulation of p53 tetramerization and nuclear export by ARC. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:20826-20831.
54. Lv P.C., Sun J., Zhu H.L. Recent advances of p53-MDM2 small molecule inhibitors (2011-present). Curr. Med. Chem 2015, 22:618-626.
55. Zhao Y., Aguilar A., Bernard D., Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment. J. Med. Chem 2015, 58:1038-1052.
56. Rudders S., Gaspar J., Madore R., Voland C., Grall F., Patel A., et al. ESE-1 is a novel transcriptional mediator of inflammation that interacts with NF-kappa B to regulate the inducible nitric-oxide synthase gene. J. Biol. Chem 2001, 276:3302-3309.
57. Grall F.T., Prall W.C., Wei W., Gu X., Cho J.Y., Choy B.K., et al. The Ets transcription factor ESE-1 mediates induction of the COX-2 gene by LPS in monocytes. FEBS J. 2005, 272:1676-1687.
58. Choi S.G., Yi Y., Kim Y.S., Kato M., Chang J., Chung H.W., et al. A novel ets-related transcription factor, ERT/ESX/ESE-1, regulates expression of the transforming growth factor-beta type II receptor. J. Biol. Chem 1998, 273:110-117.
59. Park S.H., Kim Y.S., Park B.K., Hougaard S., Kim S.J. Sequence-specific enhancer binding protein is responsible for the differential expression of ERT/ESX/ELF-3/ESE-1/jen gene in human gastric cancer cell lines: implication for the loss of TGF-beta type II receptor expression. Oncogene 2001, 20:1235-1245.
60. Walker D., Poczobutt J., Gonzales M., Horita H., Gutierrez-Hartmann A. ESE-1 is required to maintain the transformed phenotype of MCF-7 and ZR-75-1 human breast cancer cells. Open Cancer J. 2010, 3:77-88.
61. Wang J.L., Chen Z.F., Chen H.M., Wang M.Y., Kong X., Wang Y.C., et al. Elf3 drives beta-catenin transactivation and associates with poor prognosis in colorectal cancer. Cell Death Dis 2014, 5:e1263.
62. Longoni N., Sarti M., Albino D., Civenni G., Malek A., Ortelli E., et al. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-kappaB and drives prostate cancer progression. Cancer Res 2013, 73:4533-4547.
63. Manavathi B., Rayala S.K., Kumar R. Phosphorylation-dependent regulation of stability and transforming potential of ETS transcriptional factor ESE-1 by p21-activated kinase 1. J. Biol. Chem 2007, 282:19820-19830.
64. Shatnawi A., Norris J.D., Chaveroux C., Jasper J.S., Sherk A.B., McDonnell D.P., et al. ELF3 is a repressor of androgen receptor action in prostate cancer cells. Oncogene 2014, 33:862-871.
65. Chang J., Lee C., Hahm K.B., Yi Y., Choi S.G., Kim S.J. Over-expression of ERT(ESX/ESE-1/ELF3), an ets-related transcription factor, induces endogenous TGF-beta type II receptor expression and restores the TGF-beta signaling pathway in Hs578t human breast cancer cells. Oncogene 2000, 19:151-154.
66. Prescott J.D., Koto K.S., Singh M., Gutierrez-Hartmann A. The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism. Mol. Cell. Biol 2004, 24:5548-5564.
67. Lee S.H., Bahn J.H., Choi C.K., Whitlock N.C., English A.E., Safe S., et al. ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol. Cancer Ther 2008, 7:3739-3750.
68. Reya T., Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843-850.
69. Sánchez-Tilló E., de Barrios O., Siles L., Cuatrecasas M., Castells A., Postigo A. β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:19204-19209.
70. Smith G., Carey F.A., Beattie J., Wilkie M.J.V., Lightfoot T.J., Coxhead J., et al. Mutations in APC, Kirsten-ras, and p53 - alternative genetic pathways to colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:9433-9438.
71. Polakis P. Drugging Wnt signalling in cancer. EMBO J. 2012, 31:2737-2746.
72. Valenta T., Hausmann G., Basler K. The many faces and functions of [beta]-catenin. EMBO J. 2012, 31:2714-2736.
73. Martin-Belmonte F., Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat. Rev. Cancer 2012, 12:23-38.
74. Jang G.-B., Hong I.-S., Kim R.-J., Lee S.-Y., Park S.-J., Lee E.-S., et al. Wnt/β-catenin small-molecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stem-like cells. Cancer Res 2015, 75:1691-1702.
75. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
76. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol 2007, 8:221-233.
77. Mannello F., Medda V. Nuclear localization of Matrix metalloproteinases. Prog. Histochem. Cytochem 2012, 47:27-58.
78. Kwan J.A., Schulze C.J., Wang W., Leon H., Sariahmetoglu M., Sung M., et al. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J. 2004, 18:690-692.
79. Si-Tayeb K., Monvoisin A., Mazzocco C., Lepreux S., Decossas M., Cubel G., et al. Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am. J. Pathol 2006, 169:1390-1401.
80. Eguchi T., Kubota S., Kawata K., Mukudai Y., Uehara J., Ohgawara T., et al. Novel transcription factor-like function of human matrix metalloproteinase 3 regulating the CTGF/CCN2 gene. Mol. Cell. Biol 2008, 28:2391-2413.
81. Marchant D.J., Bellac C.L., Moraes T.J., Wadsworth S.J., Dufour A., Butler G.S., et al. A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity. Nat. Med 2014, 20:493-502.
82. Baek S.J., Kim K.S., Nixon J.B., Wilson L.C., Eling T.E. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol. Pharmacol 2001, 59:901-908.
83. Bootcov M.R., Bauskin A.R., Valenzuela S.M., Moore A.G., Bansal M., He X.Y., et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:11514-11519.
84. Baek S.J., Wilson L.C., Eling T.E. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 2002, 23:425-434.
85. Albertoni M., Shaw P.H., Nozaki M., Godard S., Tenan M., Hamou M.F., et al. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 2002, 21:4212-4219.
86. Tsui K.H., Hsu S.Y., Chung L.C., Lin Y.H., Feng T.H., Lee T.Y., et al. Growth differentiation factor-15: a p53- and demethylation-upregulating gene represses cell proliferation, invasion, and tumorigenesis in bladder carcinoma cells. Sci. Rep 2015, 5:12870.
87. Nakamura T., Scorilas A., Stephan C., Yousef G.M., Kristiansen G., Jung K., et al. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br. J. Cancer 2003, 88:1101-1104.
88. Senapati S., Rachagani S., Chaudhary K., Johansson S.L., Singh R.K., Batra S.K. Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene 2010, 29:1293-1302.
89. Baek S.J., Okazaki R., Lee S.H., Martinez J., Kim J.S., Yamaguchi K., et al. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 2006, 131:1553-1560.
90. Chintharlapalli S., Papineni S., Baek S.J., Liu S., Safe S. 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1. Mol. Pharmacol 2005, 68:1782-1792.
91. Jutooru I., Chadalapaka G., Chintharlapalli S., Papineni S., Safe S. Induction of apoptosis and nonsteroidal anti-inflammatory drug-activated gene 1 in pancreatic cancer cells by a glycyrrhetinic acid derivative. Mol. Carcinog 2009, 48:692-702.
92. Kelly J.A., Scott Lucia M., Lambert J.R. p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms. Cancer Lett 2009, 277:38-47.
93. Yang H., Filipovic Z., Brown D., Breit S.N., Vassilev L.T. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol. Cancer Ther 2003, 2:1023-1029.
94. Cekanova M., Lee S.H., Donnell R.L., Sukhthankar M., Eling T.E., Fischer S.M., et al. Nonsteroidal anti-inflammatory drug-activated gene-1 expression inhibits urethane-induced pulmonary tumorigenesis in transgenic mice. Cancer Prev. Res. (Phila.) 2009, 2:450-458.
95. Zimmers T.A., Gutierrez J.C., Koniaris L.G. Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer. J. Cancer Res. Clin. Oncol 2010, 136:571-576.
96. Wang X., Baek S.J., Eling T.E. The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. Biochem. Pharmacol 2013, 85:597-606.
97. Chrysovergis K., Wang X., Kosak J., Lee S.H., Kim J.S., Foley J.F., et al. NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism. Int. J. Obes. (Lond) 2014, 38:1555-1564.
98. Min K.-W., Liggett J., Silva G., Wu W., Wang R., Shen R.-F., et al. NAG-1/GDF15 Accumulates in the nucleus and modulates transcriptional regulation of the Smad pathway. Oncogene 2015, in press. 10.1038/onc.2015.95.
99. Gumbiner B.M. Regulation of cadherin-mediated adhesion in morphogenesis. Nat. Rev. Mol. Cell Biol 2005, 6:622-634.
100. Halbleib J.M., Nelson W.J. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Gene Dev 2006, 20:3199-3214.
101. Qian X., Karpova T., Sheppard A.M., McNally J., Lowy D.R. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J. 2004, 23(8):1739-1748.
102. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
103. Yilmaz M., Christofori G. Mechanisms of motility in metastasizing cells. Mol. Cancer Res 2010, 8:629-642.
104. Ferber E.C., Kajita M., Wadlow A., Tobiansky L., Niessen C., Ariga H., et al. A role for the cleaved cytoplasmic domain of E-cadherin in the nucleus. J. Biol. Chem 2008, 283:12691-12700.
105. Chetty R., Serra S., Asa S.L. Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors. Am. J. Surg. Pathol 2008, 32:413-419.
106. David J.M., Rajasekaran A.K. Dishonorable discharge: the oncogenic roles of cleaved E-cadherin fragments. Cancer Res 2012, 72:2917-2923.
107. Inge L.J., Barwe S.P., D'Ambrosio J., Gopal J., Lu K., Ryazantsev S., et al. Soluble E-cadherin promotes cell survival by activating epidermal growth factor receptor. Exp. Cell Res 2011, 317:838-848.
108. Shi Y., Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
109. Liu C., Xu P., Lamouille S., Xu J., Derynck R. TACE-mediated ectodomain shedding of the type I TGF-β receptor downregulates TGF-β signaling. Mol. Cell 2009, 35:26-36.
110. Mu Y., Sundar R., Thakur N., Ekman M., Gudey S.K., Yakymovych M., et al. TRAF6 ubiquitinates TGF[beta] type I receptor to promote its cleavage and nuclear translocation in cancer. Nat. Commun 2011, 2:330.
111. Chandra M., Zang S., Li H., Zimmerman L.J., Champer J., Tsuyada A., et al. Nuclear translocation of type I transforming growth factor β receptor confers a novel function in RNA processing. Mol. Cell. Biol 2012, 32:2183-2195.
112. Lin S.-Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol 2001, 3:802-808.
113. Xu J., Acharya S., Sahin O., Zhang Q., Saito Y., Yao J., et al. 14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. Cancer Cell 2015, 27:177-192.
114. Hsu S.-C., Hung M.-C. Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J. Biol. Chem 2007, 282:10432-10440.
115. Wang Y.N., Wang H., Yamaguchi H., Lee H.J., Lee H.H., Hung M.C. COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport. Biochem. Biophys. Res. Commun 2010, 399:498-504.
116. Wang Y.N., Lee H.H., Lee H.J., Du Y., Yamaguchi H., Hung M.C. Membrane-bound trafficking regulates nuclear transport of integral epidermal growth factor receptor (EGFR) and ErbB-2. J. Biol. Chem 2012, 287:16869-16879.
117. Lo H.-W., Ali-Seyed M., Wu Y., Bartholomeusz G., Hsu S.-C., Hung M.-C. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1. J. Cell. Biochem 2006, 98:1570-1583.
118. Eldredge E.R., Korf G.M., Christensen T.A., Connolly D.C., Getz M.J., Maihle N.J. Activation of c-fos gene expression by a kinase-deficient epidermal growth factor receptor. Mol. Cell. Biol 1994, 14:7527-7534.
119. Hanada N., Lo H.-W., Day C.-P., Pan Y., Nakajima Y., Hung M.-C. Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol. Carcinog 2006, 45:10-17.
120. Lo H.-W., Hsu S.-C., Ali-Seyed M., Gunduz M., Xia W., Wei Y., et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005, 7:575-589.
121. Li C., Iida M., Dunn E.F., Ghia A.J., Wheeler D.L. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009, 28:3801-3813.
122. Massagué J., Seoane J., Wotton D. Smad transcription factors. Gene Dev 2005, 19:2783-2810.
123. Akhurst R.J., Hata A. Targeting the TGF[beta] signalling pathway in disease. Nat. Rev. Drug Discov 2012, 11:790-811.
124. Hill C.S. Nucleocytoplasmic shuttling of Smad proteins. Cell Res 2009, 19:36-46.
125. Mullen A.C., Orlando D.A., Newman J.J., Lovén J., Kumar R.M., Bilodeau S., et al. Master transcription factors determine cell-type-specific responses to TGF-β signaling. Cell 2011, 147:565-576.
126. Warner D.R., Pisano M.M., Roberts E.A., Greene R.M. Identification of three novel Smad binding proteins involved in cell polarity. FEBS Lett 2003, 539:167-173.
127. Ellis L.R., Warner D.R., Greene R.M., Pisano M.M. Interaction of Smads with collagen types I, III, and V. Biochem. Biophys. Res. Commun 2003, 310:1117-1123.
128. Quéré R., Karlsson G., Hertwig F., Rissler M., Lindqvist B., Fioretos T., et al. Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformation. Blood 2011, 117:5918-5930.
129. Zwijsen A., Verschueren K., Huylebroeck D. New intracellular components of bone morphogenetic protein/Smad signaling cascades. FEBS Lett 2003, 546:133-139.